Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated interferon gamma (IFN-γ). We have explored whether the expression of IFNG, the gene encoding IFN-γ, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined.

Methods: Total RNA from 17 NSCLC and 21 melanoma patients was analyzed by quantitative reverse transcription PCR. STAT3 and Rantes, YAP1 and CXCL5, DNMT1, RIG1 and TET1, EOMES, IFNG, PD-L1 and CTLA4, IKBKE and NFATC1 mRNA were examined. PD-L1 protein expression in tumor and immune cells and stromal infiltration of CD8 T-cells were also evaluated. Progression-free survival and overall survival were estimated.

Results: A total of 17 NSCLC patients received nivolumab and 21 melanoma patients received pembrolizumab. Progression-free survival with nivolumab was significantly longer in NSCLC patients with high low IFNG expression (5.1 months 2 months, = 0.0124). Progression-free survival with pembrolizumab was significantly longer in melanoma patients with high low IFNG expression (5.0 months 1.9 months, = 0.0099). Significantly longer overall survival was observed for melanoma patients with high low IFNG expression (not reached 10.2 months = 0.0183). There was a trend for longer overall survival for NSCLC patients with high low IFNG expression.

Conclusions: IFN-γ is an important marker for prediction of response to immune checkpoint blockade. Further research is warranted in order to validate whether IFNG is more accurate than PD-L1.